ASCO 2016: Phase I Trial Results With Vorinostat in Head and Neck Cancer

Article

In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.

In this interview, Theodoros Teknos, MD, a Professor at The Ohio State University Medical School and Chairman for the Department of Otolaryngology (Head & Neck Surgery) at the Ohio State University Medical Center /James Cancer Hospital, sat down with the OncoTherapy Network to discuss the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.

These results were also presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7, 2016, in Chicago (abstract 6036).

Recent Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
head and neck cancer
Related Content
Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

Petosemtamab Combo Earns Breakthrough Therapy Status in PD-L1+ HNSCC

Russ Conroy
February 20th 2025
Article

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN

Tim Cortese
January 9th 2025
Article

The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.

Cisplatin/70 Gy IMRT Cemented as SOC for Nonsmoking p16+ Oropharyngeal Cancer

Cisplatin/70 Gy IMRT Cemented as SOC for Nonsmoking p16+ Oropharyngeal Cancer

Gina Mauro
September 30th 2024
Article

Experimental regimens did not cross the threshold to show superiority vs standard cisplatin plus 70 Gy radiation in those with HPV-associated oropharynx cancer.

Phase 2 data may support petosemtamab as a best-in-class treatment for frontline HNSCC, according to Jérôme Fayette, MD.

Petosemtamab Combo Shows Responses, Tolerability in Head and Neck Cancer

Kristi Rosa
June 5th 2024
Article

Phase 2 data may support petosemtamab as a best-in-class treatment for frontline HNSCC, according to Jérôme Fayette, MD.

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.

Setanaxib/Pembrolizumab Improves Survival in Head and Neck Cancer

Russ Conroy
May 8th 2024
Article

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.